|Bid||15.86 x 1100|
|Ask||15.88 x 900|
|Day's Range||15.73 - 16.45|
|52 Week Range||4.96 - 19.00|
|Beta (5Y Monthly)||-0.37|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.50|
Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Recro Pharma, Inc. (NASDAQ: REPH).
Hedge funds are not perfect. They have their bad picks just like everyone else. Facebook, a stock hedge funds have loved dearly, lost nearly 40% of its value at one point in 2018. Although hedge funds are not perfect, their consensus picks do deliver solid returns, however. Our data show the top 20 S&P 500 […]
On November 21, 2019, Recro Pharma (REPH) spun off its money losing Acute Care Drug business, in a taxable transaction. This business has historically masked the strong fundamentals of REPH's remaining CDMO business, explains Rich Howe, editor of Spin-Off Investing.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 21.) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Alnylam ...
Recro Pharma, Inc. (REPH), a high-performing, revenue generating contract development and manufacturing organization (CDMO), today announced that it has completed the spin out of its Acute Care segment, Baudax Bio. Baudax Bio common stock will begin “regular way” trading on Friday, November 22, 2019, under the symbol “BXRX” on the Nasdaq Capital Market.
Recro Pharma Inc.’s split into two businesses, both publicly traded, became official Thursday. Both Recro and its spinout, Baudax Bio, are based in Malvern and led by Gerri Henwood as president and CEO. Baudax Bio is focusing on developing and commercializing therapeutic products — including what has been Recro’s lead new drug candidate, the pain medicine intravenous meloxicam — for use in hospitals and other acute care settings.
Baudax Bio, Inc. (NASDAQ:BXRX) today announced its launch as an independent, publicly traded pharmaceutical company focused on advancing non-opioid analgesics and other products for the hospital and other acute care settings. Beginning tomorrow, November 22, 2019, Baudax will trade on the NASDAQ Capital Market under the ticker symbol “BXRX.” When-issued trading under the symbol “BXRXV” continues until market close today. “Baudax Bio will pursue the development of therapeutics, specifically focusing on innovative products for acute care settings where there is an urgent need and the potential for the greatest impact for patients,” said Gerri Henwood, President and Chief Executive Officer of Baudax Bio.
Recro Pharma, Inc. (REPH), a pharmaceutical company with a high-performing revenue generating contract development and manufacturing (CDMO) division, today announced that the U.S. Securities and Exchange Commission (SEC) has declared effective the Registration Statement on Form 10 filed by Baudax Bio Inc. Recro expects to complete the separation of Baudax Bio into an independent, publicly traded pharmaceutical company focused on advancing promising, non-opioid analgesics and other products for acute care settings on November 21, 2019. Recro’s board of directors approved the planned separation of Recro and Baudax Bio on November 5, 2019, and declared a special dividend distribution of one share of Baudax Bio common stock for every two and one half shares of Recro common stock held as of the close of business on November 15, 2019, the record date for the distribution.
Recro Pharma (REPH) delivered earnings and revenue surprises of -46.15% and 27.38%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
CDMO Business Achieves 37% Growth in 2019 Year to Date Revenues; Consolidated Company Achieves Profitability from Operations, Turns Cash Flow Positive and Raises 2019 Revenue.
MALVERN, Pa., Nov. 05, 2019 -- Recro Pharma, Inc. (NASDAQ:REPH) today announced that it will report third quarter financial results on Friday, November 8, 2019. Recro's.
Recro Pharma Inc.’s board of directors approved a plan Tuesday to spinoff its acute care business as a separate publicly traded company that will operate as Baudax Bio. Both companies will be based in Malvern and led by Gerri Henwood as president and CEO. Recro will focus on its contract manufacturing and product development business and will retain no ownership interest in Baudax Bio.
Recro Pharma, Inc. (REPH), a specialty pharmaceutical company with a high-performing revenue generating contract development and manufacturing (CDMO) division, today announced that its board of directors has approved the planned spin-off of its Acute Care business segment, which will be known as Baudax Bio, Inc. and declared a special dividend distribution of all outstanding shares of Baudax Bio common stock. For every two and one half (2.5) shares of Recro common stock held of record as of the close of business on November 15, 2019, Recro shareholders will receive one (1) share of Baudax Bio common stock.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Oct. 31) Allergan plc (NYSE: AGN ) Amgen, Inc. (NASDAQ: AMGN ...
Recro Pharma has won an appeal it filed with the Food and Drug Administration, moving a step closer to launching its first internally developed product. The Malvern-based specialty pharmaceutical company — which also said it is moving ahead with plans to spinoff its acute-care business segment —appealed the FDA’s rejection of its new drug application for intravenous meloxicam. Recro is seeking to market IV meloxicam as a non-opioid treatment to manage moderate-to-severe pain for patients in the hospital or other acute-care setting.
Recro Pharma, Inc. (REPH), a specialty pharmaceutical company with a high-performing revenue generating contract development and manufacturing (CDMO) division, today announced that it has received a written decision from the U.S. Food and Drug Administration (FDA) granting its appeal of the Complete Response Letter relating to the New Drug Application (NDA) seeking approval for intravenous (IV) meloxicam.
Recro Pharma (REPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.
If you want to know who really controls Recro Pharma, Inc. (NASDAQ:REPH), then you'll have to look at the makeup of...
Recro Pharma (REPH) delivered earnings and revenue surprises of 63.89% and 29.90%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?